Katherine J Ameringer1, Adam M Leventhal. 1. Department of Preventive Medicine, University of Southern California Keck School of Medicine, Los Angeles, California 90033, USA.
Abstract
BACKGROUND AND OBJECTIVES: Most studies of attention deficit hyperactivity disorder (ADHD) in the substance dependence literature have assessed ADHD as a single, categorical entity. This approach limits characterization across the spectrum of ADHD symptomatology and may mask differences across the two core domains of ADHD symptoms-hyperactive-impulsive (HI) and inattention (IN). Further, it is unclear whether relations of HI and IN symptoms to substance dependence extend across drug classes and to the general population. METHODS: This cross-sectional study investigated associations of lifetime ADHD HI and IN symptom levels to individual classes of lifetime substance dependence (alcohol, nicotine, depressants, opioids, stimulants, cannabis, hallucinogens, polysubstance) in a population-based sample of 34,653 American adults. RESULTS: HI and IN were associated with the majority of dependence diagnoses in a linear pattern, such that each additional symptom was associated with a proportional increase in odds of dependence. After adjusting for the overlap between symptom domains, both HI and IN uniquely associated with alcohol, nicotine, and polysubstance dependence, but only HI uniquely associated with dependence on illicit substances. CONCLUSIONS AND SCIENTIFIC SIGNIFICANCE: These findings suggest that individuals in the general population with elevated levels of ADHD (particularly HI) symptoms are at risk for various forms of substance dependence and could benefit from preventive interventions.
BACKGROUND AND OBJECTIVES: Most studies of attention deficit hyperactivity disorder (ADHD) in the substance dependence literature have assessed ADHD as a single, categorical entity. This approach limits characterization across the spectrum of ADHD symptomatology and may mask differences across the two core domains of ADHD symptoms-hyperactive-impulsive (HI) and inattention (IN). Further, it is unclear whether relations of HI and IN symptoms to substance dependence extend across drug classes and to the general population. METHODS: This cross-sectional study investigated associations of lifetime ADHD HI and IN symptom levels to individual classes of lifetime substance dependence (alcohol, nicotine, depressants, opioids, stimulants, cannabis, hallucinogens, polysubstance) in a population-based sample of 34,653 American adults. RESULTS:HI and IN were associated with the majority of dependence diagnoses in a linear pattern, such that each additional symptom was associated with a proportional increase in odds of dependence. After adjusting for the overlap between symptom domains, both HI and IN uniquely associated with alcohol, nicotine, and polysubstance dependence, but only HI uniquely associated with dependence on illicit substances. CONCLUSIONS AND SCIENTIFIC SIGNIFICANCE: These findings suggest that individuals in the general population with elevated levels of ADHD (particularly HI) symptoms are at risk for various forms of substance dependence and could benefit from preventive interventions.
Authors: E D Levin; C K Conners; D Silva; S C Hinton; W H Meck; J March; J E Rose Journal: Psychopharmacology (Berl) Date: 1998-11 Impact factor: 4.530
Authors: Nick Haslam; Ben Williams; Margot Prior; Ric Haslam; Brian Graetz; Michael Sawyer Journal: Aust N Z J Psychiatry Date: 2006-08 Impact factor: 5.744
Authors: Bridget F Grant; Deborah A Dawson; Frederick S Stinson; Patricia S Chou; Ward Kay; Roger Pickering Journal: Drug Alcohol Depend Date: 2003-07-20 Impact factor: 4.492
Authors: Albert J Arias; Joel Gelernter; Grace Chan; Roger D Weiss; Kathleen T Brady; Lindsay Farrer; Henry R Kranzler Journal: Addict Behav Date: 2008-05-13 Impact factor: 3.913
Authors: Kathryn E Gill; Ann M Chappell; Thomas J R Beveridge; Linda J Porrino; Jeffrey L Weiner Journal: Alcohol Clin Exp Res Date: 2014-08 Impact factor: 3.455
Authors: Sharlene Kaye; Josep Antoni Ramos-Quiroga; Geurt van de Glind; Frances R Levin; Stephen V Faraone; Steve Allsop; Louisa Degenhardt; Franz Moggi; Csaba Barta; Maija Konstenius; Johan Franck; Arvid Skutle; Eli-Torild Bu; Maarten W J Koeter; Zsolt Demetrovics; Máté Kapitány-Fövény; Robert A Schoevers; Katelijne van Emmerik-van Oortmerssen; Pieter-Jan Carpentier; Geert Dom; Sofie Verspreet; Cleo L Crunelle; Jesse T Young; Susan Carruthers; Joanne Cassar; Melina Fatséas; Marc Auriacombe; Brian Johnson; Matthew Dunn; Ortal Slobodin; Wim van den Brink Journal: J Atten Disord Date: 2016-02-27 Impact factor: 3.256
Authors: Patrick D Quinn; Erik Pettersson; Sebastian Lundström; Henrik Anckarsäter; Niklas Långström; Clara Hellner Gumpert; Henrik Larsson; Paul Lichtenstein; Brian M D'Onofrio Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2015-12-30 Impact factor: 3.568
Authors: Frances R Levin; John J Mariani; Sheila Specker; Marc Mooney; Amy Mahony; Daniel J Brooks; David Babb; Yun Bai; Lynn E Eberly; Edward V Nunes; John Grabowski Journal: JAMA Psychiatry Date: 2015-06 Impact factor: 21.596
Authors: Daniel P Notzon; John J Mariani; Martina Pavlicova; Andrew Glass; Amy L Mahony; Daniel J Brooks; John Grabowski; Frances R Levin Journal: Am J Addict Date: 2016-11-11